These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21335297)
21. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations]. Jahnz-Rózyk K; Targowski T; From S; Płusa T Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028 [TBL] [Abstract][Full Text] [Related]
22. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821 [TBL] [Abstract][Full Text] [Related]
23. Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective. Marton JP; Boulanger L; Friedman M; Dixon D; Wilson J; Menzin J Respir Med; 2006 Jun; 100(6):996-1005. PubMed ID: 16288858 [TBL] [Abstract][Full Text] [Related]
24. National health care costs of peripheral arterial disease in the Medicare population. Hirsch AT; Hartman L; Town RJ; Virnig BA Vasc Med; 2008 Aug; 13(3):209-15. PubMed ID: 18687757 [TBL] [Abstract][Full Text] [Related]
25. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Au DH; Udris EM; Fihn SD; McDonell MB; Curtis JR Arch Intern Med; 2006 Feb; 166(3):326-31. PubMed ID: 16476873 [TBL] [Abstract][Full Text] [Related]
26. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936 [TBL] [Abstract][Full Text] [Related]
27. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care]. Faber M; Jahnz-Rózyk K; Kucharczyk A; Targowski T; From S; Mamełka B Pol Merkur Lekarski; 2004 May; 16 Suppl 1():96-9. PubMed ID: 15524029 [TBL] [Abstract][Full Text] [Related]
28. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Lin PJ; Shaya FT; Scharf SM Respir Med; 2010 May; 104(5):697-704. PubMed ID: 19954941 [TBL] [Abstract][Full Text] [Related]
29. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Akazawa M; Biddle AK; Stearns SC Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475 [TBL] [Abstract][Full Text] [Related]
30. Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression. Albrecht JS; Park Y; Hur P; Huang TY; Harris I; Netzer G; Lehmann SW; Langenberg P; Khokhar B; Wei YJ; Moyo P; Simoni-Wastila L Ann Am Thorac Soc; 2016 Sep; 13(9):1497-504. PubMed ID: 27332765 [TBL] [Abstract][Full Text] [Related]
31. Medicaid beneficiaries with congestive heart failure: association of medication adherence with healthcare use and costs. Esposito D; Bagchi AD; Verdier JM; Bencio DS; Kim MS Am J Manag Care; 2009 Jul; 15(7):437-45. PubMed ID: 19589011 [TBL] [Abstract][Full Text] [Related]
32. Impact of regular inhaled corticosteroid use on chronic obstructive pulmonary disease outcomes. Vollmer WM; Peters D; Crane B; Kelleher C; Buist AS COPD; 2007 Jun; 4(2):135-42. PubMed ID: 17530507 [TBL] [Abstract][Full Text] [Related]
33. Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease. Au DH; Macaulay DS; Jarvis JL; Desai US; Birnbaum HG Ann Am Thorac Soc; 2015 Mar; 12(3):323-31. PubMed ID: 25642649 [TBL] [Abstract][Full Text] [Related]
34. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Raebel MA; Delate T; Ellis JL; Bayliss EA Med Care; 2008 Oct; 46(10):1116-22. PubMed ID: 18815534 [TBL] [Abstract][Full Text] [Related]
35. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Hanania NA Clin Ther; 2007 Oct; 29(10):2121-33. PubMed ID: 18042470 [TBL] [Abstract][Full Text] [Related]
36. Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis. Ajmera M; Raval AD; Shen C; Sambamoorthi U Int J Chron Obstruct Pulmon Dis; 2014; 9():339-48. PubMed ID: 24748785 [TBL] [Abstract][Full Text] [Related]
37. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Lin PJ; Fillit HM; Cohen JT; Neumann PJ Alzheimers Dement; 2013 Jan; 9(1):30-8. PubMed ID: 23305822 [TBL] [Abstract][Full Text] [Related]
38. Assessment of the impact of medication therapy management delivered to home-based Medicare beneficiaries. Welch EK; Delate T; Chester EA; Stubbings T Ann Pharmacother; 2009 Apr; 43(4):603-10. PubMed ID: 19318600 [TBL] [Abstract][Full Text] [Related]
39. Management and survival of patients admitted with an exacerbation of COPD: comparison of two Danish patient cohorts. Eriksen N; Vestbo J Clin Respir J; 2010 Oct; 4(4):208-14. PubMed ID: 20887343 [TBL] [Abstract][Full Text] [Related]
40. Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Eaton T; Young P; Fergusson W; Moodie L; Zeng I; O'Kane F; Good N; Rhodes L; Poole P; Kolbe J Respirology; 2009 Mar; 14(2):230-8. PubMed ID: 19272084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]